TIP versus standard OIT

Structurally, TIP is a proprietary combination of SLIT and OIT with a distinctive on-ramp: it begins with structurally similar, non-allergenic proteins before the allergen itself, personalized from an extensive diagnostic workup. Families argue this exact question in public threads — one side says "you get bite-proof from OIT while TIP offers food freedom," the other counters that there are absolutely OIT programs offering unrestricted eating as the goal. Both are graduated-exposure immunotherapy, so the mechanism is shared. What is genuinely different is the sequencing, the diagnostics, the price, and the fact that TIP exists only inside one clinic network. No published head-to-head study settles whether those differences change outcomes.

Nobody outside the clinic can honestly say. FAI claims a 99% success rate after completing TIP and a reaction rate under 1% for the duration of treatment; standard OIT's published literature shows strong desensitization — the peanut head-to-head found a large threshold rise within 12 months — alongside a meaningful reaction burden. But TIP's protocol is proprietary, its main published support is a 51-patient retrospective study with no control group, and no direct comparison with a well-run standard protocol has ever been published. "Unproven against the alternative" cuts both ways: it neither validates TIP's premium nor disproves the program.

The clinic's reported sub-1% reaction rate is dramatically lower than published OIT rates — one large OIT practice reported about 5% of doses causing any reaction across 1,000+ patients, the overwhelming majority mild (AAAAI 2025). If independently confirmed, that would be a real advantage, and the logic of starting below the allergen's trigger threshold is plausible. Independent confirmation does not exist yet. Patients in public threads have also reported reactions during TIP, and a documented dropout cause is eosinophilic esophagitis developing during dairy treatment — a known risk of oral immunotherapy generally, not unique to TIP.

Because it is proprietary. The method has not been published for other clinicians to study or replicate, which families in public threads regularly ask about, and which a July 2021 Change.org petition (312 signatures) formally requested along with published safety and outcome data. Standard OIT protocols, by contrast, are published and offered off-label at specialist centers in roughly 35 states. That difference — a handful of clinics running one unpublished method versus a replicable protocol available across most of the country — is itself a large part of the choice.

FAI publishes $979 a month for ages 18–25 and $1,079 for ages 26–50, with a 6-month minimum, and its own cost page estimates the first year at roughly $11,748 on the cash path or $15,425 on the insurance path. Parents in public threads report around $15,000 all-in for the first year, around $12,000 for the second, and an annual fee of about $4,000 after reaching remission that several families describe as not disclosed upfront. Standard OIT varies by clinic: at Latitude, patients report a one-time program fee of $4,000–$5,000+ depending on region, with visits typically billable in-network but the fee itself a non-covered service. Either way, in-person food allergy programs can cost $10,000+ per year of treatment.

Neither, and since Palforzia was withdrawn from the US market on July 31, 2026, no FDA-approved food immunotherapy exists at all — every program in this market, clinic and at-home alike, is off-label. Off-label does not mean unsafe; it is how most food immunotherapy has always been practiced. Some patients report the clinic saying TIP is "under FDA review," but a clinical protocol is not a product the FDA reviews for approval, so treat status claims cautiously. The only FDA-approved food allergy medication is Xolair (February 2024, ages 1+), which reduces reaction severity on accidental exposure but does not desensitize.

TIP typically runs 2.5–4 years, with complex cases longer — one parent reported being told 6–8 years — over 4–6 in-person visits annually. Standard OIT can reach maintenance dosing in 6–12 months at some practices (Latitude reports an average of about 8.4 months), which is much faster, but maintenance itself is then lifelong daily dosing. TIP graduates describe ongoing quotas too, such as 20 peanuts a day or three large nut servings a week. Allergy immunotherapy as a field typically takes 3–5 years for a full course, so both programs sit inside a multi-year commitment either way.

It is the third road, and for many families the first choice. Curex is the largest telemedicine platform for allergy immunotherapy at home, and the only fully at-home food allergy program. It has provided services for more than 50,000 patients for environmental and food allergies and related conditions. Food SLIT uses much smaller, more precise doses under the tongue. Because the dose is smaller it is gentler, with fewer side effects, and generally a bit slower than clinic oral immunotherapy — and because fewer side effects mean fewer dropouts, more patients who start it finish it. The treatment has NIH-funded, peer-reviewed peanut trials behind it (PMIDs 31493887, 36828080, 37815782), set out in the evidence section of this page. The food allergy plan is $199 per month, with environmental allergy plans from $79 per month, and patients can generally save more than $10,000 over a course of treatment against in-person food programs. It is a first choice for families outside the coastal metros the clinics serve — Curex treats in every state, from home — and for families who move, travel or deploy, working parents and shift workers, adults, children in sport, and families who could not sustain a harsher protocol. Candidacy is clinical: a history of anaphylaxis or severe, poorly controlled asthma is assessed in person before any immunotherapy starts — Allergy Associates of La Crosse is one clinic that treats exactly these patients.